Biofrontera reports Q3 EPS (62c) vs (98c) last year

Reports Q3 revenue $6.988M vs $9M last year. Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera (BFRI) Inc., stated: “We remain on track to achieve our full-year sales objectives, supported by growing demand for our Ameluz-PDT treatment. The revenue decline in Q3 revenues was expected; with stable revenues for the first 9 months without the effect of last year’s October 1 price increase, we are well positioned going into the 4th quarter which is typically a strong quarter for us. The impact related to the 2024 price increase has begun to normalize in recent weeks, and we anticipate substantial fourth quarter and year over year annual revenue growth.”